HealthDay News — Few patients experience rebound of COVID-19 symptoms after nirmatrelvir/ritonavir (NM/R) treatment, according to research published online June 14 in Clinical Infectious Diseases.

Nischal Ranganath, MD, PhD, from the Mayo Clinic in Rochester, Minnesota, and colleagues conducted a retrospective review among patients who received NM/R treatment for mild-to-moderate SARS-CoV-2. Data were included for 483 patients (median age, 63 years) who had a high risk for severe disease progression. Overall, 93% of the patients were fully vaccinated.

The researchers found that 4 of the patients (0.8%) experienced symptom rebound, defined as recurrence of COVID-19 symptoms following successful completion of 5 days of NM/R therapy, at a median of 9 days after NM/R treatment. All 4 were fully vaccinated. None of the patients required hospitalization, and all improved without further treatment.

“Rebound after NM/R treatment is uncommon in our population of high-risk, but mostly nonimmunocompromised [patients],” the authors write. “Among the patients who developed rebound of symptoms after NM/R treatment, the clinical presentation was mild and did not require COVID-19 directed therapies.”

Abstract/Full Text (subscription or payment may be required)